CSI Market
Sign In | Register

Avadel Pharmaceuticals Plc (AVDL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AVDL Annual Cash Flow →
The table below presents a historical view of Avadel Pharmaceuticals Plc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income0.02
Depreciation & amortization3.01
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-4.04
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation14.43
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Available For Sale Securities Gross Realized Gain Loss Net-
Grants Recognized In Other Income And Income From Operations-
Interest Expense-
Increase Decrease In Research And Development Tax Credit Receivable-
Acquisition Related Contingent Consideration Remeasurement-
Marketable Securities Gain Loss-
Noncash Gain Loss Deconsolidation Of Subsidiary-
Research And Development Expense Acquired In Process Cost20.00
Income taxes-1.05
Unrealized Gain (Loss) on Securities0.00
Increase (Decrease) in Accounts Receivable-8.35
Increase (Decrease) in Accounts Payable5.07
Increase (Decrease) in Accrued Liabilities-1.50
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-1.56
Other Working Capital-4.11
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities26.67
Investing Activities
Capital Expenditures-0.19
Sale of Capital Items0.00
Proceeds from Sale of Available-for-sale Securities, Debt57.74
Payments to Acquire Marketable Securities-46.92
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development-15.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-4.37
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.18
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-51.37
Earnout Payments For Acquisition-
Earn Out Payment-
Interest Expense On Consideration-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents51.37
Proceeds Received In Advance Of Share Issuance-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.18
Effect of exchange rate on cash flow1.96
Discontinued operations0.00
Free Cash Flow26.48
Total Cash Flow28.44
4 historic quarters locked

Sign in to unlock the full Avadel Pharmaceuticals Plc cash flow history.

Sign In Create Free Account

About Avadel Pharmaceuticals Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001012477-25-000031

Figures are derived from filed reports and may be restated. Historical data is subject to revision.